Comparison of the effectiveness between 4 weeks and 8 weeks treatment of lansoprazole in iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000488

Enrollment

Registered

2012-07-23

Start date

2010-07-02

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : (1)Lansoprazole(Lanston)Capsule 30mg, 4weeks, qd(quaque die),qm(every morning),ac(before meals), po(par os=by mouth) treatment (2)Lansoprazole(Lanston) Capsule 30mg, 8weeks, qd(quaque die),qm(e

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: EMR was indicated in patients with adenoma accompanied by any degree of dysplasia and in patients with early superficial gastric cancer.

Exclusion criteria

Exclusion criteria: ?coexistence of peptic ulcer ?coexistence of concomitant illness influencing anti-ulcer effect of PPI, such as systemic vasculitis, Behcet`s disease, eosinophilic gastritis?use of aspirin, non-steroidal anti inflammatory drug or glucocorticoid within 7 days of EMR ?pregnant women

Design outcomes

Primary

Measure	Time frame
ulcer stage at 8 weeks after endoscopic mucosal resection	—

Secondary

Measure	Time frame
Ulcer reduction ratio was determined by dividing the ulcer dimension (maximal diameter x diameter perpendicular to the maximal diameter) at 8 weeks after EMR by the initial ulcer dimension.;factors affecting complete healing of EMR-induced ulcer	—

Countries

Korea, Republic of

Contacts

Public ContactChangHwan CHOI

Chung-Ang Univerisity Hospital

Outcome results